OPTC and retinal vascular disorder: These results, coupled with the finding that pharmacological overexpression of the OPTC gene prevents hypoxia-induced neovascularization, suggest that opticin-specific inhibitors can be developed as promising therapeutic targets for the treatment of diseases associated with abnormal angiogenesis such as retinal vascular disorders and other proliferative vascular diseases.